The use of sibutramine in the management of obesity and related disorders: An update

Figures & data

Table 1 Effects of sibutramine on obesity and related disorders

Anthropometric parameters	Effect
Body weight	↓
Body mass index	↓
Waist circumference	↓
Waist/hip ratio	↓
Body fat	↓ (Particularly abdominal fat)
Cardiometabolic parameters
Metabolic risk factors
HDL cholesterol	↑
Triglycerides	↓
LDL cholesterol	→
HbA1c levels	↓ (in diabetic patients)
Serum uric acid levels	↓
Inflammatory markers
High-sensitivity C-reactive protein	↓
Pro-inflammatory cytokines (TNF-α, IL-6)	↓
Anti-inflammatory cytokines (IL-10)	↑
Serum adipokine levels
Leptin	↓ or →
Adiponectin	↑ or →
Resistin	↓
Endothelial function	(+)
Left ventricular hypertrophy	↓
Nonalcoholic steatohepatitis	(+)
Blood pressure	↑
Pulse rate	↑
Obesity-related disorders
Sleep apnea syndrome	Possible (+)
Polycystic ovary syndrome	(+)
Binge eating disorder	(+)
Hypothalamic obesity	Possible (+)

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; TNF-α, tumor necrosis factor-α; HbA_1c, glycosylated hemoglobin A₁; IL-6, interleukin-6; IL-10, interleukin-10; →, no effect; ↓, decrease; ↑, increase; (+), improvement.